- Method for Distinguishing Mesenchymal Stem Cell Using Molecular Marker and Use Thereof
-
Disclosed is a method for distinguishing a mesenchymal stem cell comprising, using at least one gene selected from the genes having the nucleotide sequences indicated by the accession numbers shown in Table 1 as a distinguish marker, detecting the difference in expression of the distinguish marker between a mesenchymal stem cell and a connective tissue cell to distinguish the mesenchymal stem cell from the connective tissue cell. This method enables to distinguish an undifferentiated mesenchymal stem cell from other connective tissue cell such as fibroblasts, osteoblasts, chondrocytes and adipose cells with good accuracy. A mesenchymal stem cell given by this method or a composition comprising the mesenchymal stem sell can be used as a therapeutic for use in the regenerative medicine.
- -
-
-
- Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors
-
We have discovered potent and selective xanthine PDE5 inhibitors. Compound 25 (PDE5 IC50=0.6 nM, PDE6/PDE5=101) demonstrated similar functional efficacy and PK profile to Sildenafil (PDE5 IC50=3.5 nM, PDE6/PDE5=7).
- Wang, Yuguang,Chackalamannil, Samuel,Hu, Zhiyong,Boyle, Craig D.,Lankin, Claire M.,Xia, Yan,Xu, Ruo,Asberom, Theodros,Pissarnitski, Dmitri,Stamford, Andrew W.,Greenlee, William J.,Skell, Jeffrey,Kurowski, Stanley,Vemulapalli, Subbarao,Palamanda, Jairam,Chintala, Madhu,Wu, Ping,Myers, Joyce,Wang, Peng
-
p. 3149 - 3152
(2007/10/03)
-
- Structure-activity relationships in a series of xanthine derivatives with antibronchoconstrictory and bronchodilatory activities
-
Thirty-one 1,3,7,8-substituted xanthine derivatives have been synthesized and evaluated for bronchodilator and anti-bronchoconstrictory activities in in vitro tracheal relaxation and in vivo bronchospasm inhibition models. Activity tests have been complemented with phosphodiesterase inhibition and toxicological data. Structure-activity relationships are discussed. Compound 21 (1,3-diisobutyl-8-methylxanthine) has been selected for further pharmacological development because of its good activity profile and favourable therapeutic index, which is 14- and 38-fold greater than that of theophylline and IBMX, respectively.
- Merlos,Gomez,Vericat,Bartroli,Garcia-Rafanell,Forn
-
p. 653 - 658
(2007/10/02)
-